Frequent(may affect up to 1 in 10 patients):
Unknown frequency(cannot be estimated from available data):
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor, even if it is a possible adverse effect not listed in this prospectus. You can also report them directly through the Spanish System of Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the bottle and on the packaging after the letters «CAD».The expiration date is the last day of the month indicated.
This medication does not require special conservation conditions.
Medications should not be thrown into the drains or trash. Dispose of the containers and medications you no longer need at the SIGRE collection pointat the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medications you no longer need. By doing so, you will help protect the environment.
Composition of Restafos
Appearance of the product and contents of the packaging
Restafos are white to off-white, oval-shaped, film-coated tablets with "SVL" engraved on one side.
HDPE bottles with polypropylene caps.
Each bottle contains 180, 200, or 210 tablets.
Packs containing 1, 2, or 3 bottles are available.
Only some packaging sizes may be marketed.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
SPA Società Prodotti Antibiotici S.p.A.
Via Biella, 8
20143 Milano
Italy
Responsible for manufacturing
Synthon Hispania S.L.
C/ Castelló nº1. Polígono Las Salinas, 08830 Sant Boi de Llobregat
Barcelona. Spain
You can request more information about this medication by contacting the local representative of the holder of the marketing authorization:
SPA Farma Ibérica S.L.U.
Carrer de Roc Boronat, 147
08018 Barcelona
Spain
This medication is authorized in the member states of the European Economic Area with the following names:
Denmark: Sevelamercarbonat Zentiva
Spain: Restafos 800 mg film-coated tablets
United Kingdom (Northern Ireland): Sevelamer carbonate
Last review date of this leaflet: June 2022
"Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/ "
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.